UT SOUTHWESTERN MEDICAL CENTER
Novel endogenous and engineered activators of STING: from mechanisms to cancer therapy
Novel endogenous and engineered activators of STING: from mechanisms to cancer therapy is a funding opportunity from UT SOUTHWESTERN MEDICAL CENTER, up to 642739, closing March 31, 2030.
Mar 31, 2030
(1339d left)Overview
STING is an ER-associated membrane innate immune protein vital for cancer defense. Despite promising preclinical results, STING agonists have not shown significant success in early clinical trials due to complex signaling, transient activation as a result lysosomal degradation, and detrimental side-effects on healthy…